WHEN Danaher Corporation’s high bid for Vision Systems Limited of Melbourne, Australia, was accepted last month, it appeared to be simply another acquisition by a large U.S. manufacturer. But, in fact, there are four reasons this transaction is significant to pathologists in the United States and worldwide. If approved by Vision’s shareholders later this year, […]
- "Molecular Diagnostics Update"
Ventana & Cytyc Fall Short, Danaher Wins the Prize
Goal was Vision Systems’ molecular markers and product line for histology laboratories
- By Robert Michel
- > From the Volume XIII No. 15 - November 6, 2006 Issue
